Adherium announced that the Food and Drug Administration (FDA) has granted clearance for the over-the-counter (OTC) sale of the Hailie sensor (previously known as Smartinhaler) for expanded use with ProAir HFA (albuterol sulfate; Teva), Ventolin HFA (albuterol; GlaxoSmithKline), and Flovent HFA (fluticasone propionate; GlaxoSmithKline) inhalers.
Prior to today’s FDA clearance, the Hailie platform was intended for use with Symbicort (budesonide, formoterol fumarate dihdyrate; AstraZeneca). The Hailie sensor attaches to the asthma or chronic obstructive pulmonary disease (COPD) inhaler to monitor and help with patient adherence. The device tracks medication use, provides a usage history, and reminds the patient when it is time to take a dose.
ProAir HFA and Ventolin HFA are beta-2 agonists indicated to treat bronchospasm in patients aged ≥4 years. Flovent HFA is a steroid indicated for maintenance treatment of asthma as prophylactic therapy in patients aged ≥4 years.
An online portal will be available for healthcare professionals to access patient-group data and reports from the Hailie sensors. Through Bluetooth technology, clinicians and patients will be able to share and monitor inhaler usage.
For more information visit Hailie.com.
This article originally appeared on MPR